Literature DB >> 15893904

In vitro nonspecific mitogenic response of T-cell subsets in acute and chronic brucellosis.

Sami Kinikli1, Nuran Turkcapar, Murat Bulent Kucukay, Goksal Keskin, Gulay Kinikli.   

Abstract

The aim of the present study was to determine the cellular immune response on the course of brucellosis by investigating the proliferation response of T-cell subsets to phytohemagglutinin (PHA), that is, nonspecific mitogen in the patients with acute and chronic brucellosis. The study was performed in 19 patients with untreated brucellosis (acute, n = 11; chronic, n = 8) and 19 healthy controls. Standard tube agglutination and Coombs tests for brucellosis were performed. CD4+ and CD8+ T cell were investigated by the flow cytometry and sorting methods in all of cases. After these cells were cultured and stimulated with PHA, [H3]-thymidine uptake and stimulation indices (SIs) were established. In all of the patients with brucellosis, CD4+ SIs and CD8+ SIs were found to be 1.40 +/- 0.63 and 1.45 +/- 0.42, respectively, and in the controls CD4+ SIs and CD8+ SIs were 1.59 +/- 0.36 and 1.64 +/- 0.37, respectively. In acute cases, CD4+ SIs were 1.71 +/- 0.64 and CD8+ SIs were 1.54 +/- 0.45. CD4+ SIs were 0.97 +/- 0.25 and CD8+ SIs were 1.32 +/- 0.37 in chronic cases. Although in acute cases CD4+ SIs and CD8+ SIs were not different from those in the control group, CD4+ SIs of chronic brucellosis cases were found to be significantly low as compared with those of acute brucellosis cases and the controls (P < 0.01). CD8+ SIs of acute and chronic brucellosis cases were not found to be different from those in the controls. Brucella agglutination titers of the patients with acute and chronic brucellosis were not found related with CD4 SIs and CD8 SIs. The findings of significantly low results of CD4+ T-cell proliferative responses of chronic brucellosis to PHA as compared with control and acute brucellosis cases remind that the development of chronic infection might be a result of T-helper proliferation defect.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15893904     DOI: 10.1016/j.diagmicrobio.2005.02.016

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  6 in total

1.  Evaluation of Regulatory T Cells in Patients with Acute and Chronic Brucellosis.

Authors:  Ali Ganji; Ghasem Mosayebi; Ehsanollah Ghaznavi-Rad; Khadije Khosravi; Nader Zarinfar
Journal:  Rep Biochem Mol Biol       Date:  2017-04

2.  CD80/CD28 co-stimulation in human brucellosis.

Authors:  P Skendros; P Boura; F Kamaria; M Raptopoulou-Gigi
Journal:  Clin Exp Immunol       Date:  2006-12       Impact factor: 4.330

3.  Brucella melitensis T cell epitope recognition in humans with brucellosis in Peru.

Authors:  Anthony P Cannella; Cecilia S Lindestam Arlehamn; John Sidney; Kailash P Patra; Katherine Torres; Renee M Tsolis; Li Liang; Philip L Felgner; Mayuko Saito; Eduardo Gotuzzo; Robert H Gilman; Alessandro Sette; Joseph M Vinetz
Journal:  Infect Immun       Date:  2013-10-14       Impact factor: 3.441

Review 4.  Meta-Analysis of the Changes of Peripheral Blood T Cell Subsets in Patients with Brucellosis.

Authors:  Rongjiong Zheng; Songsong Xie; Shaniya Niyazi; Xiaobo Lu; Lihua Sun; Yan Zhou; Yuexin Zhang; Kai Wang
Journal:  J Immunol Res       Date:  2018-05-17       Impact factor: 4.818

5.  Antigen-specific acquired immunity in human brucellosis: implications for diagnosis, prognosis, and vaccine development.

Authors:  Anthony P Cannella; Renee M Tsolis; Li Liang; Philip L Felgner; Mayuko Saito; Alessandro Sette; Eduardo Gotuzzo; Joseph M Vinetz
Journal:  Front Cell Infect Microbiol       Date:  2012-02-01       Impact factor: 5.293

6.  Chronic brucellosis patients retain low frequency of CD4+ T-lymphocytes expressing CD25 and CD28 after Escherichia coli LPS stimulation of PHA-cultured PBMCs.

Authors:  Panagiotis Skendros; Alexandros Sarantopoulos; Konstantinos Tselios; Panagiota Boura
Journal:  Clin Dev Immunol       Date:  2009-01-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.